Literature DB >> 26629437

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

Jody C Chuang1, Joel W Neal1.   

Abstract

Entities:  

Year:  2015        PMID: 26629437      PMCID: PMC4630528          DOI: 10.3978/j.issn.2218-6751.2015.03.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  13 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

3.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

4.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

5.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

6.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

7.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

8.  Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.

Authors:  Masayuki Takeda; Isamu Okamoto; Kazuhiko Nakagawa
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

9.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

10.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

View more
  9 in total

Review 1.  Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

Authors:  Roberto Chalela; Víctor Curull; César Enríquez; Lara Pijuan; Beatriz Bellosillo; Joaquim Gea
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Authors:  Annamaria Catino; Andrea Misino; Anna Scattone; Lucia Caldarola; Stella Petroni; Antonio Logroscino; Elisabetta Sara Montagna; Gabriella Serio; Giovanni Simone; Domenico Galetta
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 3.  MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.

Authors:  Hannah Petrek; Ai-Ming Yu
Journal:  Pharmacol Res Perspect       Date:  2019-12

4.  Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting.

Authors:  Elena Sultova; C Benedikt Westphalen; Andreas Jung; Joerg Kumbrink; Thomas Kirchner; Doris Mayr; Martina Rudelius; Steffen Ormanns; Volker Heinemann; Klaus H Metzeler; Philipp A Greif; Anna Hester; Sven Mahner; Nadia Harbeck; Rachel Wuerstlein
Journal:  Diagnostics (Basel)       Date:  2021-04-20

5.  Exploring the Synergistic Anticancer Potential of Benzofuran-Oxadiazoles and Triazoles: Improved Ultrasound- and Microwave-Assisted Synthesis, Molecular Docking, Hemolytic, Thrombolytic and Anticancer Evaluation of Furan-Based Molecules.

Authors:  Ali Irfan; Sadia Faiz; Azhar Rasul; Rehman Zafar; Ameer Fawad Zahoor; Katarzyna Kotwica-Mojzych; Mariusz Mojzych
Journal:  Molecules       Date:  2022-02-02       Impact factor: 4.411

Review 6.  Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.

Authors:  Xing Chang; Zi Liu; Shuai Man; Annie Roys; Zengqiang Li; Daiying Zuo; Yingliang Wu
Journal:  RSC Adv       Date:  2019-06-07       Impact factor: 4.036

Review 7.  Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.

Authors:  Eleni Zografos; Foteinos-Ioannis Dimitrakopoulos; Angelos Koutras
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

8.  Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.

Authors:  Arlou Kristina Angeles; Petros Christopoulos; Zhao Yuan; Simone Bauer; Florian Janke; Simon John Ogrodnik; Martin Reck; Matthias Schlesner; Michael Meister; Marc A Schneider; Steffen Dietz; Albrecht Stenzinger; Michael Thomas; Holger Sültmann
Journal:  NPJ Precis Oncol       Date:  2021-12-07

9.  Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

Authors:  Leora Horn; Ziping Wang; Gang Wu; Elena Poddubskaya; Tony Mok; Martin Reck; Heather Wakelee; Alberto A Chiappori; Dae Ho Lee; Valeriy Breder; Sergey Orlov; Irfan Cicin; Ying Cheng; Yunpeng Liu; Yun Fan; Jennifer G Whisenant; Yi Zhou; Vance Oertel; Kim Harrow; Chris Liang; Li Mao; Giovanni Selvaggi; Yi-Long Wu
Journal:  JAMA Oncol       Date:  2021-11-01       Impact factor: 31.777

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.